According to CRI’s market research, the sales of Osimertinib have increased sharply since it entered the Chinese market. The sales revenue in 2020 was approximately CNY1.54 billion in China. Although the growth rate of Osimertinib slowed down last year, Osimertinib still has the highest rate in the Chinese pharmaceutical market. The CAGR of sales value of Osimertinib in China was 451.7% in 2017 to 2020.

CRI analyzes the sales of Osimertinib will keep increasing as the market expands. The potential of market expansion depends on three aspects. Firstly, the increase in new cases of lung cancer patients will increase the demand for Osimertinib. The average number of new lung patients in China is about 730,000 people. In 2020, there were approximately 820,000 new patients which 80%-85% of them are NSCLC patients. A large number of patients drives the demand for medication. Secondly, the increase in the number of approved indications for Osimertinib will bring new target patients. Lastly, after renewing the national medical insurance drug list, patients may benefit more from the price reduction for the Osimertinib, which will also lead the sales volume of Osimertinib to increase.

Topics Covered:
-The impact of COVID-19 on China’s Osimertinib market
– Sales value and volume of China’s Osimertinib 2016-2020
– Competitive landscape of China’s Osimertinib market
– Prices of Osimertinib in China
– Prices of Osimertinib in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Osimertinib market
– Prospect of China’s Osimertinib market from 2021 to 2025

The post Investigation Report on China’s Osimertinib Market 2021-2025 first appeared on CRI Report.